Literature DB >> 3310672

Antipsychotic effect of buprenorphine in schizophrenia.

C Schmauss1, A Yassouridis, H M Emrich.   

Abstract

The antipsychotic potency of the partial opiate agonist buprenorphine was evaluated in 10 neuroleptic-free schizophrenic patients suffering from frequent hallucinations, delusions, and severe formal thought disorders. Buprenorphine had a pronounced antipsychotic effect, which lasted about 4 hours, in patients with schizophreniform disorders (N = 4) and paranoid schizophrenia (N = 3).

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3310672     DOI： 10.1176/ajp.144.10.1340

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


  10 in total

1.  Personality measures in former heroin users receiving methadone or in protracted abstinence from opiates.

Authors:  L J Cohen; E Gertmenian-King; L Kunik; C Weaver; E D London; I Galynker
Journal:  Acta Psychiatr Scand       Date:  2005-08       Impact factor: 6.392

Review 2.  New-Onset Psychotic Symptoms Following Abrupt Buprenorphine/Naloxone Discontinuation in a Female Patient with Bipolar Disorder: A Case Report.

Authors:  Yezhe Lin; Alexander D Zhang; Ching-Fang Sun; Justin B White; Ansi Qi; Jessica A Farrell; Robert L Trestman; Rachel K Martin; Anita S Kablinger
Journal:  Psychopharmacol Bull       Date:  2022-06-27

3.  Medications Development for the Treatment of Nicotine Dependence in Individuals with Schizophrenia.

Authors:  Ivan D Montoya; Frank Vocci
Journal:  J Dual Diagn       Date:  2007-11

Review 4.  New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone.

Authors:  Michael Soyka
Journal:  Subst Abuse Rehabil       Date:  2015-01-06

5.  Psychopathological symptoms of patients with heroin addiction entering opioid agonist or therapeutic community treatment.

Authors:  Pier Paolo Pani; Emanuela Trogu; Federica Vigna-Taglianti; Federica Mathis; Roberto Diecidue; Ursula Kirchmayer; Laura Amato; Marina Davoli; Joli Ghibaudi; Antonella Camposeragna; Alessio Saponaro; Fabrizio Faggiano; Angelo Giovanni Icro Maremmani; Icro Maremmani
Journal:  Ann Gen Psychiatry       Date:  2014-11-18       Impact factor: 3.455

Review 6.  Toward the Identification of a Specific Psychopathology of Substance Use Disorders.

Authors:  Angelo G I Maremmani; Pier Paolo Pani; Luca Rovai; Silvia Bacciardi; Icro Maremmani
Journal:  Front Psychiatry       Date:  2017-04-27       Impact factor: 4.157

7.  The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: a randomized, double-blind, clinical trial.

Authors:  Jamshid Ahmadi; Mina Sefidfard Jahromi; Zahra Ehsaei
Journal:  Trials       Date:  2018-08-29       Impact factor: 2.279

8.  Withdrawal Emergent Recurrent Manic Episodes with Use of "Bhukki": A Case Report.

Authors:  Neetu K Nandan; Lokesh Kumar Singh; Sai Krishna Tikka; Avinash Shukla
Journal:  Indian J Psychol Med       Date:  2020-11-02

9.  Psychopathology and Urine Toxicology in Methadone Patients.

Authors:  Gamal Sadek; Zack Cernovsky; Simon Chiu
Journal:  Ment Illn       Date:  2015-06-23

10.  Opioid antagonists are associated with a reduction in the symptoms of schizophrenia: a meta-analysis of controlled trials.

Authors:  Samuel D Clark; Jared X Van Snellenberg; Jacqueline M Lawson; Anissa Abi-Dargham
Journal:  Neuropsychopharmacology       Date:  2020-06-09       Impact factor: 7.853
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.